3-(4-chlorophenyl)-2-methylpropanoic acid | 1012-17-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(4-chlorophenyl)-2-methylpropanoic acid
• CAS: 1012-17-5
• 化学式: C₁₀H₁₁ClO₂
• mdl: MFCD08445717
• 分子量: 198.649
• InChiKey: DFLJNMPGPGFGBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  3-(4-chlorophenyl)-2-methylpropanoic acid 在 硫酸 、 溶剂黄146 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 20.5h， 生成 ethyl 2-(5-chloro-2-methyl-1H-inden-3-yl)acetate
  参考文献：
  名称：

  Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation

  摘要：

  RXR alpha represents an intriguing and unique target for pharmacologic interventions. We recently showed that Sulindac and a designed analog could bind to RXR alpha and modulate its biological activity, including inhibition of the interaction of an N-terminally truncated RXR alpha (tRXR alpha) with the p85 alpha regulatory subunit of phosphatidylinositol-3-OH kinase (PI3K). Here we report the synthesis, testing and SAR of a series of novel analogs of Sulindac as potential modulators for inhibiting tRXR alpha-dependent AKT activation. A new compound 30 was identified to have improved biological activity. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.01.012
• 作为产物：
  描述：

  3-(4-chlorophenyl)-3-methyl-2-acrylic acid 在 甲醇 、 magnesium 作用下， 以80.03%的产率得到3-(4-chlorophenyl)-2-methylpropanoic acid
  参考文献：
  名称：

  胰岛素合成剂的2-苯氧基/ 2-（4-异丙烯基苄氧基）-2-甲基-3-（4-取代的苯基）丙酸的脂肪酸合成剂：RSR 13-15和PKR 13-15

  摘要：

  标题化合物（RSR 13-15）和（PKR 13-15）分别通过将苄醇和4-异丙基苄醇分别与-2-溴-2-甲基-3-（4-取代苯基）丙酸酯进行醚化而制得在THF中的氢化钠存在下，然后将乙酯进行碱水解。该合成顺序中使用的取代的丙酸是通过镁-甲醇还原相应取代的丙酸制备的，而丙酸则是通过4-取代的苯甲醛与丙酸酐的“珀金反应”制备的。报道了制备具有这些化合物几乎所有结构特征的所有这些化合物的合成序列的细节，所述结构特征充当有效的胰岛素增敏剂。

  DOI：

  10.1007/s00044-004-0109-4

文献信息

• Ligand-controlled divergent dehydrogenative reactions of carboxylic acids via C–H activation
  作者：Zhen Wang、Liang Hu、Nikita Chekshin、Zhe Zhuang、Shaoqun Qian、Jennifer X. Qiao、Jin-Quan Yu

  DOI：10.1126/science.abl3939

  日期：2021.12.3

  inaccessible with existing carbonyl desaturation protocols. Product inhibition is overcome through ligand-promoted preferential activation of C(sp3)–H bonds over C(sp2)–H bonds or a tandem dehydrogenation or vinyl C–H alkynylation sequence. The dehydrogenation reaction is compatible with molecular oxygen as the terminal oxidant.

  通过亚甲基 C-H 活化将烷基链脱氢转化为烯烃仍然是一个重大挑战。我们报道了两类吡啶-吡啶酮配体，它们通过钯催化的β-亚甲基C-H活化羧酸实现不同的脱氢反应，从而直接合成α,β-不饱和羧酸或γ-亚烷基丁烯内酯。这对反应的定向性质允许在其他烯醇化官能团（例如酮）存在下对羧酸进行化学选择性脱氢，从而提供现有羰基去饱和方案无法实现的化学选择性。通过配体促进的 C(sp 3 )–H 键相对于 C(sp 2 )–H 键的优先激活或串联脱氢或乙烯基 C–H 炔基化序列来克服产物抑制。脱氢反应与分子氧作为末端氧化剂相容。
• Tetronic and tetramic acids
  申请人：Godel Thierry

  公开号：US20050119329A1

  公开（公告）日：2005-06-02

  This invention relates to new tetronic and tetramic acid derivatives with beta-secretase inhibitory activity of formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 5′ , R 6 and R 6′ are as defined hereinabove, to processes for their preparation, compositions containing said tetronic and tetramic acid derivatives and their use in the treatment and prevention of diseases modulated by an inhibitor of β-secretase, such as Alzheimer's disease.

  这项发明涉及具有β-分泌酶抑制活性的新四元和四酰胺衍生物的化学式I： 其中R1、R2、R3、R4、R5、R5'、R6和R6'如上所定义，以及它们的制备过程、含有所述四元和四酰胺衍生物的组合物以及它们在治疗和预防由β-分泌酶抑制剂调节的疾病中的用途，如阿尔茨海默病。
• Weak, bidentate chelating group assisted cross-coupling of C(sp³)–H bonds in aliphatic acid derivatives with aryltrifluoroborates
  作者：Zhihua Cai、Shangda Li、Yuzhen Gao、Lei Fu、Gang Li

  DOI：10.1039/c8cc07481j

  日期：——

  A protocol of Pd(II)-catalyzed, weak bidentate directing group assisted β-C(sp3)–H activation/cross-coupling with organoboron reagents has been achieved, affording arylation of aliphatic acid derivatives that contain α-hydrogen atoms in moderate to good yields. The potential of this method for an asymmetric β-C(sp3)–H arylation via desymmetrization was also presented.

  已实现了由Pd（II）催化的弱双齿指导基团辅助的β-C（sp 3）-H活化/与有机硼试剂交叉偶联的方案，使含α-氢原子的脂肪族酸衍生物芳构化高产。还介绍了该方法通过去对称化进行不对称β-C（sp 3）-H芳构化的潜力。
• [EN] NEW ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSÉS ISOINDOLINE OU ISOQUINOLÉINE, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：SERVIER LAB

  公开号：WO2015011164A1

  公开（公告）日：2015-01-29

  Compounds of formula (I): (I) wherein Het, R3, R4, R5, R7, R8, R9, T, p, p', q, and q' are as defined in the description are pro-apoptotic agents useful in the treatment of cancers and of auto-immune and immune system diseases.

  式(I)的化合物：其中Het、R3、R4、R5、R7、R8、R9、T、p、p'、q和q'的定义如描述中所定义，是在治疗癌症以及自身免疫和免疫系统疾病中有用的促凋亡剂。
• [EN] ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES<br/>[FR] BENZIMIDAZOLES SUBSTITUÉS PAR UN ISOXAZOLYLE
  申请人：CELLCENTRIC LTD

  公开号：WO2016170324A1

  公开（公告）日：2016-10-27

  A compound which is a benzimidazolyl isoxazole of formula (I): wherein: R0and R, which are the same or different, are each H or C1-6 alkyl; R9, R9 and R9, which are the same or different, are each H or F; X is -(alkn-, -alk-C(=O)-NR-, -alk-NR-C(=O)- or -alk-C(=O)-; R1 is selected from -S(=O)2R'; a 4- to 6-membered, C-linked heterocyclic group which is unsubstituted or substituted; and an N-linked spiro group of the following formula: R2 and R2', which are the same or different, are each H or C1-6 alkyl, or R2 and R2' form, together with the C atom to which they are attached, a C3-6 cycloalkyl group; R3 and R3, which are the same or different, are each H, C1-6 alkyl, OH or F; R4 is phenyl or a 5- to 12-membered, N-containing heteroaryl group and is unsubstituted or substituted; alk is C1-6 alkylene; R' is C1-6 alkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.

  一种化合物，是一种具有以下结构的苯并咪唑基异唑烷（I）：其中：R0和R，相同或不同，分别为H或C1-6烷基；R9，R9和R9，相同或不同，分别为H或F；X为-(烷基-，-烷基-C(=O)-NR-，-烷基-NR-C(=O)-或-烷基-C(=O)-；R1从-S(=O)2R'，未取代或取代的4-至6-成员的C-连接的杂环基，以及以下式的N-连接的螺环基中选择：R2和R2'，相同或不同，分别为H或C1-6烷基，或者R2和R2'与它们连接的C原子一起形成C3-6环烷基；R3和R3，相同或不同，分别为H，C1-6烷基，OH或F；R4为苯基或未取代或取代的含氮5-至12-成员的杂芳基；烷基为C1-6烷基；R'为C1-6烷基；n为0或1；或其药用盐。该化合物具有调节p300和/或CBP活性的作用，并用于治疗癌症，特别是前列腺癌。